The gamma variant was first identified in Brazil and Japan. It has markedly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment, but other EUA monoclonal antibody treatments are available. Reduced neutralization by convalescent and post-vaccination sera.
The delta strain, first identified in India, has rapidly risen to dominance in the United States and in many parts of the world, likely due to a significantly higher transmissibility rate. It can spread through fleeting transmission and required less time post-infection to become transmissible. Delta shows significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment, though other EUA monoclonal antibody treatments are available. Delta also displays reduced neutralization by convalescent and post-vaccination sera.
First identified in South Africa, the Beta variant shows ~50% increased transmission and significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment, though other EUA monoclonal antibody treatments are available. Beta also displays reduced neutralization by convalescent and post-vaccination sera.
The alpha variant was first identified in the United Kingdom. The variant's attributes include 50% increased transmission, potential increased severity, (based on hospitalizations and case fatality rates). No impact on susceptibility to emergency use authorization (EUA) monoclonal antibody treatments. Minimal impact on neutralization by convalescent and post-vaccination sera.